GWSG
VNDA icon

GPS Wealth Strategies Group’s Vanda Pharmaceuticals VNDA Stock Holding History

GPS Wealth Strategies Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed -$117 – 1445
2024
Q3 		$117 Hold
25
– – ﹤0.01% 1369
2024
Q2 		$141 Hold
25
– – ﹤0.01% 1328
2024
Q1 		$103 Buy
+25
New +$100 ﹤0.01% 1231

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GPS Wealth Strategies Group's VNDA Position: Q4 2024 in Review

GPS Wealth Strategies Group sold out of Vanda Pharmaceuticals (VNDA) in Q4 2024, closing a stake of 25 shares — an estimated $117 sold.

GPS Wealth Strategies Group first reported a position in VNDA in Q1 2024 and held it in 3 quarters. The position peaked at $141 in Q2 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

  • GPS Wealth Strategies Group reported no remaining Vanda Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GPS Wealth Strategies Group sold 25 Vanda Pharmaceuticals shares in Q4 2024, an estimated $117.
  • GPS Wealth Strategies Group first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • GPS Wealth Strategies Group's Vanda Pharmaceuticals position peaked at $141 in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on GPS Wealth Strategies Group's 13F filing for Q4 2024, filed 24 Jan 2025.